Author:
Suzumiya Junji,Takizawa Jun
Funder
Kyowa Hakko Kirin
Chugai Pharmaceutical
Astellas Pharma
Eisai
Takeda Pharmaceutical Company
Celgene
Janssen Pharmaceuticals
Bristol-Myers Squibb
AbbVie
AstraZeneca
Shin-Nihon Kagaku
Sanofi
Ono Pharmaceutical
Nippon Shinyaku
Dainippon Sumitomo Pharma
Mochida Pharmaceutical Company
Daiichi-Sankyo
MSD K.K.
Publisher
Springer Science and Business Media LLC
Reference95 articles.
1. Campo E, Ghia P, Montserrat E, Harris NL, Müller-Hermelink HK, Stein H, et al. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. World Health Organization classification of tumors. Lyon: IARC Press; 2017. p. 216–221.
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60.
3. Hallek M. On the architecture of translational research designed to control chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Prog. 2018;2018(1):1–8.
4. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266–87.
5. Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, et al. Kyushu Hematology Organization for Treatment (K-HOT) Study Group. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 2001;67(3):152–7.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献